# Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement

> **NIH NIH R37** · BRIGHAM AND WOMEN'S HOSPITAL · 2021 · $381,309

## Abstract

ABSTRACT: The ability to predict the optimal therapy for an individual patient is a major unmet need
in the treatment of cancer and other diseases. The majority of therapies in clinical cancer treatment,
particularly cytotoxics as well as combinations of multiple drugs, have no reliable predictor of response.
This uninformed therapy selection is highly inefficient and likely leads to reduced therapeutic success
rates, increased side effects and excessive economic expenditures. I develop novel “lab-in-a-patient”
technology to probe, monitor, and eventually treat disease in real time within human tissue. A tiny,
minimally invasive device will provide continuous output of information that reveals disease biology
and informs treatment options.
“Lab-in-a-patient” technology has the potential to act as a micro-pathology laboratory by allowing the
real-time measurement of response to multiple therapies or other chemical perturbagens simultaneously
within the patient. We have achieved proof-of-concept for release of microdoses of a large number of
distinct drugs or molecular “sensors” in parallel into native tissue, with analysis of the effect for each
such compound (Science Translational Medicine, 284ra57, 2015). We are augmenting this technology with
miniaturized detection methods that enable optical in situ real-time monitoring of disease state and the
effects of small molecules and biologics near each drug reservoir. This blend of high-throughput
chemical perturbation and optical detection in a single instrument will, for the first time, enable
diseased tissue to be monitored and functionally characterized in a continuous and noninvasive
manner. It will thus provide unprecendented detail, precision and speed of analyzing response and
resistance to therapeutics through live in situ readouts of signaling pathways, metabolites and other
molecular markers.
This approach may eventually push medicine away from trial-and-error treatments with longer-term
macroscale endpoints and towards precision management of disease by probing, treating and
monitoring locally at the microscale level. Use of the technology for local delivery of biological (non-
therapeutic) probes into native tissue creates the capability for fundamental insights through direct
stimulus-response measurements with real-time in situ monitoring, particularly in the areas of
immunology, metabolism and cancer formation where the local tissue microenvironment plays a key
role in the molecular processes underlying disease biology. In the fullness of time, these devices may
enable individualized and real-time selection of optimal therapies and could facilitate rational design of
more effective, personalized therapeutic regimens in numerous cancer indications. The proposed project
spans continued technological and translational development that support eventual commercialization.

## Key facts

- **NIH application ID:** 10116316
- **Project number:** 5R37CA224144-04
- **Recipient organization:** BRIGHAM AND WOMEN'S HOSPITAL
- **Principal Investigator:** Oliver Jonas
- **Activity code:** R37 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $381,309
- **Award type:** 5
- **Project period:** 2018-03-15 → 2022-02-28

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10116316

## Citation

> US National Institutes of Health, RePORTER application 10116316, Implantable microdevices with integrated optical imaging for high-throughput in situ tumor response and drug sensitivity measurement (5R37CA224144-04). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10116316. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*